Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial
Single-fraction stereotactic ablative radiotherapy (SABR) is a safe and effective therapy for non-central lung tumors [1 –3]. Three randomized trials have found similar local control and toxicity rates when comparing single versus multi-fraction SABR [1–3]. Compared to fractionated regimens, single-fraction SABR is more cost-effective with less time burden for patients [4,5]. Chest wall toxicity is less well studi ed for single-fraction SABR, however, and there is debate as to whether proximity to the chest wall is a relative contraindication for single-fraction treatment [6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 26, 2024 Category: Radiology Authors: Brianna Lau, Yufan F. Wu, Sunan Cui, Jie Fu, Scott Jackson, Daniel Pham, Piotr Dubrowski, Shaila Eswarappa, Lawrie Skinner, Hiroki Shirato, Hiroshi Taguchi, Michael F. Gensheimer, Harriet Gee, Alexander L. Chin, Maximilian Diehn, Billy W. Loo, Vitali Mois Source Type: research
Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
Non-small-cell lung cancer (NSCLC) accounts for 80 –85 % of all lung cancer cases. Approximately 30 % of patients with NSCLC are diagnosed with stage III disease [1], which is usually associated with a higher risk of recurrences (about one-third of patients) and poorer outcomes compared to other early stages [2]. Owing to an inherent heterogen eity, treatment approaches for stage III NSCLC vary depending on patients' distinct characteristics. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 26, 2024 Category: Radiology Authors: Juan Li, Shun Lu, Yuke Tian, Lan Jiang, Lu Li, Shao-Hua Xie, Qiang Li Tags: Original Article Source Type: research
LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/ STIM1 axis
This study investigated the effects and mechanism of LINC00313 in nasopharyngeal carcinoma. It was found that LINC00313 was increased in NPC tissues and cells. LINC00313 knockdown enhanced autophagy, and decreased stemness and cell viability of NPC cells through regulating STIM1. Besides, METTL3/IGF2BP1-mediated m6A modification promoted the stabilization and up-regulation of LINC00313. LINC00313 activated AKT/mTOR pathway in NPC cells through PTBP1/STIM1 axis. All the results demonstrated that upregulation of LINC00313 suppressed autophagy and promoted stemness of NPC cells through PTBP1/STIM1 axis. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 25, 2024 Category: Radiology Authors: Lina Xu, Sile Liu, Yang Yang, Lu Shu, Yi Sun Tags: Original Article Source Type: research
Randomized self-controlled study comparing open-face vs. closed immobilization masks in fractionated cranial radiotherapy
Radiotherapy is an essential part in the management of primary and metastatic brain tumors. To ensure safe and reproducible delivery of radiotherapy, accurate patient positioning and immobilization is required. The standard-of-care immobilization for fractionated brain irradiation, as for head-and-neck cancer, is an individually made thermoplastic mask which is closed around the patient ’s face. Closed masks provide stability, accuracy and reproducibility of each treatment fraction [1,2,3]. The inter- and intrafraction accuracy described by setup and head motion uncertainties for intracranial radiotherapy are reportedly ...
Source: Radiotherapy and Oncology - April 25, 2024 Category: Radiology Authors: Mich èle Keane, Nienke Weitkamp, Indira Madani, Jonathan Day, Riccardo Dal Bello, Mariangela Zamburlini, Antonia Schiess, Amanda Moreira, Sophie Perryck, Katja Tomuschat, Marilyn Spencer, Stephanie Tanadini-Lang, Matthias Guckenberger, Michelle Brown Tags: Original Article Source Type: research
A joint physics and radiobiology DREAM team vision – Towards better response prediction models to advance radiotherapy
RT is one of the cornerstones of cancer treatment. However, it comes with inevitable radiation dose to normal tissues. Achieving best possible treatment outcome for individual patients through informed selection of modalities and their careful application requires a quantitative description of their contribution to tumour control and side-effects with the help of models (see Table 1). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 24, 2024 Category: Radiology Authors: C. Vens, P. van Luijk, R.I. Vogelius, I. El Naqa, L. Humbert-Vidan, C. von Neubeck, N. Gomez-Roman, E. Bahn, L. Brualla, T.T. B öhlen, S. Ecker, R. Koch, A. Handeland, S. Pereira, L. Possenti, T. Rancati, D. Todor, B. Vanderstraeten, M. Van Heerden, W. U Tags: Review Article Source Type: research
Lexicographic optimization-based planning for stereotactic radiosurgery of brain metastases
Nowadays, automation has found an ideal environment in radiation oncology helping to guarantee high-quality treatments [1,2,3,4], with a high level of standardization and harmonization, reducing the burden of a growing number of highly demanding procedures [5]. In particular, stereotactic radiosurgery (SRS) significantly impacts on institutional workload being the first option for patients with up to 10 brain metastases (BM) according to international guidelines [6,7,8,9,10]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 24, 2024 Category: Radiology Authors: Sara Trivellato, Paolo Caricato, Roberto Pellegrini, Martina Camilla Daniotti, Sofia Bianchi, Bianca Bordigoni, Stefano Carminati, Valeria Faccenda, Denis Panizza, Gianluca Montanari, Stefano Arcangeli, Elena De Ponti Tags: Original Article Source Type: research
Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study
Nasopharyngeal carcinoma (NPC) is prevalent in southern China and exhibits a significant propensity for distant metastasis [1]. The incidence of distant metastasis in NPC ranges from 10 % to 30 % [2–4], and the prognosis for patients with metastatic nasopharyngeal carcinoma (mNPC) is generally unfavorable [5]. Considering the intricate nature of mNPC, comprehensive multidisciplinary treatment approaches are required. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 24, 2024 Category: Radiology Authors: Yang Liu, Jie Ma, Xiao-Yi Zeng, Zhi-Chao Zuo, Rui-Zhong Chen, Xiao-Yu Li, Zhong-Guo Liang, Kai-Hua Chen, Xin-Bin Pan, Su Pei, Bin-Bin Yu, Ling Li, Song Qu, Yun-Li Yang, Xiao-Dong Zhu Tags: Original Article Source Type: research
Aims+Scope/Editorial Board/ Publication information
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Source Type: research
Contents
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Source Type: research
Image guided radiotherapy in curative treatment for prostate cancer. 5-year results from a randomized controlled trial (RIC-trial)
Medical advances in health care are in many cases subject to stringent systems of approval including requests for phase III-IV trials prior to implementation in routine clinical practice [1]. By contrast, technological advances are more often subject to non-formal approval and the evidence base for clinical effects is often weaker. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Authors: Jo- Åsmund Lund, Stian Lydersen, Bjørg Aksnessæther, Arne Solberg, Anne Wanderås, Christoffer Lervåg, Stein Kaasa, Hanne Tøndel Tags: Original Article Source Type: research
ESHO 1 –85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology
The first systematical clinical study of heat as a method to improve radiation response in tumors was reported in 1910 by M üller, who described the potential of using local diathermia as an adjuvant to radiotherapy [1,2]. However, it was not until the mid-1970′s that the concept began to be more detailed explored. This took place through numerous smaller uncontrolled studies, which strongly suggested that adjuvant hy perthermia may increase the probability of controlling tumors by radiotherapy [3–7]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Authors: Jens Overgaard, Maarten CCM Hulshof, Olav Dahl, Giorgio Arcangeli, on behalf of the ESHO clinical committee Tags: Original Article Source Type: research
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial
Patient-reported outcome (PRO) metrics, including health-related quality of life (HRQoL), are becoming an increasingly important element of clinical trials, including radiotherapy trials. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Authors: Saskia A. Cooke, Jos é S.A. Belderbos, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M.T. Dieleman, Judi N.A. van Diessen, Jan-Jakob Sonke, Dirk de Ruysscher Tags: Original Article Source Type: research
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas
We thank Elmali et al. [1] for the points they raised regarding our paper. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 21, 2024 Category: Radiology Authors: Kelvin Ken Yu, Adam Yeo, Samuel Ngan, Julie Chu, David Chang, Shankar Siva, Aaron Wong, Tomas Kron, Nick Hardcastle, Mathieu Gaudreault, Therese Chesson, Siena Williams, Mark Burns, Sarat Chander Tags: Letter to the Editor Source Type: research
Towards a European prospective data registry for particle therapy
The evidence for the value of particle therapy (PT) is still sparse. While randomized trials remain a cornerstone for robust comparisons with photon-based radiotherapy, data registries collecting real-world data can play a crucial role in building evidence for new developments. This Perspective describes how the European Particle Therapy Network (EPTN) is actively working on establishing a prospective data registry encompassing all patients undergoing PT in European centers. Several obstacles and hurdles are discussed, for instance harmonization of nomenclature and structure of technical and dosimetric data and data protec...
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Cai Grau, Alexandru Dasu, Esther G.C. Troost, Karin Haustermans, Damien C. Weber, Johannes A. Langendijk, Vincent Gregoire, Ester Orlandi, Juliette Thariat, Neige Journy, Abdulhamid Chaikh, Aurelie Isambert, Barbara Alicja Jereczek-Fossa, Ana Vaniqui, Pav Tags: Perspective Source Type: research
Durvalumab impacts progression-free survival while high-dose radiation > 66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Lung cancer is still the most prominent cause for cancer-related deaths worldwide [1]. The majority of patients are diagnosed with non-small cell lung cancer (NSCLC), 30 % of which present in locally advanced stage III [2]. Since the landmark publication by Antonia et al. the standard of care (SoC) for unresectable NSCLC stage III is concomitant chemoradiotherapy (cCRT) 60 – 66 Gy in 2 Gy fractions followed by Durvalumab for one year [3–6]. Although cCRT is preferably recommended by multiple prospective trials [7–11] and one meta-analysis [12], sequential regimens are still frequently used, especially in elder...
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Franz Zehentmayr, Petra Feurstein, Elvis Ruznic, Brigitte Langer, Brane Grambozov, Marisa Klebermass, Herbert H üpfel, Johann Feichtinger, Danijela Minasch, Martin Heilmann, Barbara Breitfelder, Claudia Steffal, Gisela Gastinger-Grass, Karoline Kirchhamm Tags: Original Article Source Type: research
